Obesity diagnosis should move beyond a single definition based solely on body mass index (BMI), researchers said after analyzing health data from 844,108 adults in China, the UK, the US and Spain.
The findings, published in the journal Nature, show that current methods of diagnosing obesity may fail to distinguish people who already have health problems linked to excess body fat from those who are at increased risk but do not yet show signs of impaired organ function.
“People with obesity, like everyone else, deserve care that matches their needs: no less and no more,” said Professor Francesco Rubino, senior author of the study and chair of metabolic and bariatric surgery at King’s College London, in a press release.
Obesity is currently usually classified using body mass index, a measure calculated from a person’s height and weight. However, BMI does not account for how much body fat a person actually has, how it is distributed throughout the body or whether it is already affecting their health.
In January 2025, a commission whose findings were published in The Lancet Diabetes & Endocrinology proposed a new approach to diagnosing obesity that goes beyond BMI alone. It recommends distinguishing between two conditions: clinical obesity, in which excess body fat impairs organ function or interferes with daily activities, and preclinical obesity, in which excess body fat increases health risks but normal bodily function is preserved.
Researchers from King’s College London and an international team of co-authors set out to test whether the proposed approach provides more accurate identification of obesity and prediction of subsequent health outcomes.
Their analysis showed that BMI alone both overestimated and underestimated the prevalence of obesity across the four groups studied. Adding waist circumference and waist-to-height ratio to BMI assessments reduced misclassification: BMI alone failed to identify obesity based on body fat levels in up to 8.6% of participants and incorrectly classified up to 3.1% as having obesity, Euronews reports. The researchers also found that clinical obesity accounted for 23% to 31% of all obesity cases, with a prevalence in the general population of 5.6% to 10.9%.
Importantly, the two categories were associated with markedly different health outcomes. Clinical obesity was linked to a substantially higher risk of death, while preclinical obesity was associated with a moderate increase in risk.
Most people classified as having preclinical obesity at the start of the study—77% to 91% across the different groups—did not progress to clinical obesity over ten years.
“Body mass index alone cannot tell us whether a person is already ill or merely at risk of disease, or what care they need, leaving people vulnerable to both undertreatment and overtreatment,” Rubino noted.
“Preclinical obesity should therefore not automatically be regarded as an active disease, but neither should it be considered harmless. Some people may need preventive treatment, but its intensity should match their individual risk,” he added.
According to the authors, this distinction could help healthcare professionals identify more accurately who needs treatment for an existing disease and who would benefit more from preventive interventions, rather than applying the same approach to everyone with a high BMI.










